Loading clinical trials...
Loading clinical trials...
Clinical Trial Comparing Two Electroconvulsive Therapy (ECT) Application Schemas in Ultra-resistant Schizophrenia
The effects of the ECT in schizophrenia ultra-resistant were studied in short times (4-6 months in most studies with follow-up). The literature identified a high relapse rate of 32% in the weeks to months after ECT discontinuation. The use of the ECT in the prevention of the relapse is partially known. In an empirical way, experts recommend protocols of prevention of the relapse going from 6 to 12 months. Nevertheless, the profit of a long cure (12 months) compared with a short cure (6 months) was never determined. Therefore, the investigators decided to lead a prospective randomized controlled study in order to compare the response rates between the two strategies of clozapine and ECT combinations applied to URS patients. The treatment consisted either in a short therapy of six months or a longer course of therapy of twelve months. To the investigators' knowledge, it is the first study which compares two ECT strategies (both the short duration and the longer one) for the treatment of URS patients.
Age
18 - 55 years
Sex
ALL
Healthy Volunteers
No
Centre Hospitalier Charles Perrens
Bordeaux, France
Centre Hospitalier de Cadillac
Cadillac, France
CHU de Caen
Caen, France
Clermont-Ferrand Hospital
Clermont-Ferrand, France
Montpellier University Hospital
Montpellier, France
CHU de Nantes
Nantes, France
EPS Ville Evrard
Neuilly-sur-Marne, France
Centre Hospitalier Saint Anne
Paris, France
Centre Hospitalier Henri Laborit
Poitiers, France
CHU de Toulouse
Toulouse, France
Start Date
July 4, 2018
Primary Completion Date
October 4, 2023
Completion Date
October 4, 2023
Last Updated
September 16, 2020
64
ESTIMATED participants
Electroconvulsive therapy
DEVICE
Lead Sponsor
Centre Hospitalier du Rouvray
Collaborators
NCT07455929
NCT06740383
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions